Videos and webinars

1. How CDMOs Are Evolving To Serve A Diverse And Emerging CGT Market 1/12/2026

   This segment of Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing featuring expert panelists Steve Awad, Principal Director, Supply Chain & Industry X — Life Sciences, Accenture, and Michael Blackton, MBA, VP, Manufacturing and Supply at Ocugen, explored how the CDMO landscape is adapting to support the growing diversity of CGT modalities, particularly for small and mid-sized developers that often lack in-house capabilities.

2. Digital Strategies Driving Efficiency And Throughput In CGT Manufacturing 1/12/2026

   This segment of Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing featuring expert panelists Steve Awad, Principal Director, Supply Chain & Industry X — Life Sciences, Accenture, and Michael Blackton, MBA, VP, Manufacturing and Supply at Ocugen focused on how digital and operational innovation is reshaping efficiency, cost control, and capacity planning in CGT manufacturing.

3. Capacity, Risk, And The Role Of Digital Innovation 1/12/2026

   This portion of Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing featuring expert panelists Steve Awad, Principal Director, Supply Chain & Industry X — Life Sciences, Accenture, and Michael Blackton, MBA, VP, Manufacturing and Supply at Ocugen focused on how developers can assess whether a CDMO is truly equipped to support multimodal programs without introducing capacity bottlenecks, quality drift, or compliance risk. Our experts emphasized that credible CDMOs demonstrate both process maturity through documented, consistently followed planning practices and digital maturity with robust capacity models and simulation tools rather than ad hoc spreadsheets.

4. Scaling Quality And Managing Cost Pressures Across CGTs 1/12/2026

   During Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing featuring expert panelists Steve Awad, Principal Director, Supply Chain & Industry X — Life Sciences, Accenture, and Michael Blackton, MBA, VP, Manufacturing and Supply at Ocugen examined how CGT developers can scale quality organizations without creating unsustainable overhead, while also addressing the distinct cost pressures of cell versus gene therapy manufacturing.

5. Workforce Readiness And A Final Checklist For Multi-Modal CDMO Selection 1/12/2026

   The closing segment of Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing featuring expert panelists Steve Awad, Principal Director, Supply Chain & Industry X — Life Sciences, Accenture, and Michael Blackton, MBA, VP, Manufacturing and Supply at Ocugen emphasized that true multi-modal readiness depends as much on people and governance as on facilities and technology. Our experts stressed the importance of a deeply trained, modality-specific workforce, shaped by practical factors such as geographic access to skilled aseptic operators, alongside robust training strategies to build talent where gaps exist.

6. Choosing The Right CDMO In A Multi-Modal CGT Landscape 1/12/2026

   Our first segment of Driving Efficiency, Reducing Costs in Multi-Modal CGT Manufacturing featuring expert panelists Steve Awad, Principal Director, Supply Chain & Industry X — Life Sciences, Accenture, and Michael Blackton, MBA, VP, Manufacturing and Supply at Ocugen set the stage for how cell and gene therapy developers are rethinking outsourcing as pipelines expand beyond single modalities, weighing the tradeoffs between using one multimodal CDMO versus multiple specialized partners.

7. A Better Way For Closed-System Processing In Cell Therapy 12/1/2025

   Small changes in aseptic processing can yield major operational improvements. Streamlining closed-system connections helps reduce contamination risks, supports scalability, and lowers manufacturing costs.

8. Modular Systems Explained 9/3/2025

   Modular bioprocessing systems offer fast, flexible manufacturing. They require reliable connectors to facilitate, protect, and manage fluid flow from the beginning of the process to final fill-finish.

9. Innovations In CGT Processing 6/3/2025

   Discover insights into how innovative connectors streamline workflows, save time, and enhance reliability in critical applications, ultimately supporting improved outcomes in cell and gene therapies.

10. Innovations In Sterile Connectors Transform CGT Bioprocessing 4/21/2025

    Explore advancements in single-use sterile connectors transforming CGT bioprocessing by enhancing fluid handling, reducing contamination, and improving process reliability for next-gen therapies.